Published in Ophthalmology on May 22, 2013
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.76
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol (2013) 0.93
Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts. Adv Ther (2016) 0.75
Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. BMC Ophthalmol (2016) 0.75
A genome-wide association study identified a novel genetic loci STON1-GTF2A1L/LHCGR/FSHR for bilaterality of neovascular age-related macular degeneration. Sci Rep (2017) 0.75
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol (2001) 21.37
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology (2012) 4.70
Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol (2010) 4.50
Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology (2006) 4.48
The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol (2005) 4.46
Age-related macular degeneration. Lancet (2012) 4.17
Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology (2007) 3.85
A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol (2005) 3.74
Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol (2011) 3.24
Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology (2007) 3.08
Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci (2005) 2.94
Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2013) 2.82
Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol (1997) 2.41
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond) (2011) 2.05
Ten-year incidence and progression of age-related maculopathy: the blue Mountains Eye Study. Ophthalmology (2007) 1.86
Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J AAPOS (2009) 1.76
Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.73
Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70
Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol (2011) 1.69
Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci (2009) 1.66
Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol (2011) 1.64
Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol (2010) 1.55
Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina (2007) 1.39
Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol (2011) 1.32
Risk factors for choroidal neovascularization and vision loss in the fellow eye study of CNVPT. Retina (2003) 1.18
Genetics of age-related macular degeneration: current concepts, future directions. Semin Ophthalmol (2011) 1.16
Age-related macular degeneration and risk factors for the development of choroidal neovascularization in the fellow eye. Curr Opin Ophthalmol (1998) 1.08
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. Clin Ophthalmol (2011) 1.08
Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema. Retina (2011) 1.07
Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS (2012) 0.99
Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol (2010) 0.98
Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina (2011) 0.97
Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy. Eur J Ophthalmol (2012) 0.97
Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group. Arch Ophthalmol (2007) 0.87
Association of ARMS2 genotype with bilateral involvement of exudative age-related macular degeneration. Am J Ophthalmol (2012) 0.87
Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol (2008) 0.79
Genetic, behavioral, and sociodemographic risk factors for second eye progression in age-related macular degeneration. Invest Ophthalmol Vis Sci (2012) 0.78
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology (2006) 9.01
Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol (2003) 4.78
Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology (2006) 4.48
Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A (2010) 4.30
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol (2008) 3.14
Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2013) 2.82
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology (2003) 2.61
Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med (2007) 2.54
Defects in RGS9 or its anchor protein R9AP in patients with slow photoreceptor deactivation. Nature (2004) 2.48
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina (2006) 2.23
Retinal pigment epithelial changes after macular hole surgery with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol (2002) 2.20
Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology (2012) 2.19
Utility of intraoperative optical coherence tomography during vitrectomy surgery for vitreomacular traction syndrome. Retina (2014) 2.15
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev (2014) 1.95
POSTNATAL SERUM INSULIN-LIKE GROWTH FACTOR I AND RETINOPATHY OF PREMATURITY. Retina (2016) 1.93
Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina (2009) 1.88
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87
Identifying and eliminating the roadblocks to comparative-effectiveness research. N Engl J Med (2010) 1.84
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina (2007) 1.82
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A (2008) 1.70
Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70
Sutureless scleral fixation of intraocular lenses: outcomes of two approaches. The 2014 Yasuo Tano Memorial Lecture. Graefes Arch Clin Exp Ophthalmol (2014) 1.59
Stereoacuity of preschool children with and without vision disorders. Optom Vis Sci (2014) 1.58
Retinopathy and cognitive impairment in adults with CKD. Am J Kidney Dis (2012) 1.58
Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.57
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology (2003) 1.54
Progression to severe retinopathy predicted by retinal vessel diameter between 31 and 34 weeks of postconception age. Arch Ophthalmol (2007) 1.52
Association of risk factors for choroidal neovascularization in age-related macular degeneration with decreased foveolar choroidal circulation. Am J Ophthalmol (2010) 1.47
Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers. Mol Cell Proteomics (2009) 1.39
Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging (2005) 1.38
Effect of isometric exercise on choroidal blood flow in patients with age-related macular degeneration. Br J Ophthalmol (2010) 1.38
Pathological findings in eyes with the ganciclovir implant. Ophthalmology (2005) 1.38
Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies. Ophthalmology (2008) 1.35
The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology (2011) 1.34
Intravitreal triamcinolone acetonide for diabetic macular edema. Retina (2005) 1.33
Foveolar choroidal hemodynamics in proliferative diabetic retinopathy. Int Ophthalmol (2004) 1.27
Cause and prognosis of nontraumatic sixth nerve palsies in young adults. Ophthalmology (2002) 1.23
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol (2008) 1.23
Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology (2008) 1.20
White dot syndromes: a 20-year study of incidence, clinical features, and outcomes. Ocul Immunol Inflamm (2011) 1.19
Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol (2010) 1.19
Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina (2014) 1.18
Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.18
Retinopathy and chronic kidney disease in the Chronic Renal Insufficiency Cohort (CRIC) study. Arch Ophthalmol (2012) 1.16
The CHOP postnatal weight gain, birth weight, and gestational age retinopathy of prematurity risk model. Arch Ophthalmol (2012) 1.15
Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina (2014) 1.15
Cyclophosphamide for ocular inflammatory diseases. Ophthalmology (2009) 1.14
Interaction between the photoreceptor-specific tubby-like protein 1 and the neuronal-specific GTPase dynamin-1. Invest Ophthalmol Vis Sci (2007) 1.14
A novel segmentation algorithm for volumetric analysis of macular hole boundaries identified with optical coherence tomography. Invest Ophthalmol Vis Sci (2013) 1.13
Primary intraocular lymphoma: clinical, cytologic, and flow cytometric analysis. Ophthalmology (2004) 1.11
Tubby-like protein 1 (TULP1) interacts with F-actin in photoreceptor cells. Invest Ophthalmol Vis Sci (2005) 1.08
Semiautomated analysis of retinal vessel diameter in retinopathy of prematurity patients with and without plus disease. Am J Ophthalmol (2006) 1.07
Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.07
Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy. Arch Ophthalmol (2005) 1.06
A 32 kb critical region excluding Y402H in CFH mediates risk for age-related macular degeneration. PLoS One (2011) 1.05
Re: Factors determining visual outcome in endogenous Candida endophthalmitis. Retina (2013) 1.05
Association between retinopathy and cardiovascular disease in patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC] Study). Am J Cardiol (2012) 1.04
Chemical Characterization of Polysaccharide from the Slime Layer of the Cyanobacterium Microcystis flos-aquae C3-40. Appl Environ Microbiol (1991) 1.04
Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol (2008) 1.03
Current knowledge and trends in age-related macular degeneration: today's and future treatments. Retina (2013) 1.02
Early synaptic defects in tulp1-/- mice. Invest Ophthalmol Vis Sci (2009) 1.02
Endophthalmitis after anti-VEGF injections. Ophthalmology (2009) 1.01
SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS: What Is the Evidence? Retina (2015) 1.01
Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol (2002) 1.00
Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion. Retina (2011) 1.00
Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina (2009) 0.99
Hypopyon in patients with uveitis. Ophthalmology (2009) 0.99
Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS (2012) 0.99
Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology (2012) 0.97
Effect of Viagra on the foveolar choroidal circulation of AMD patients. Exp Eye Res (2005) 0.97
Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome. Am J Ophthalmol (2007) 0.96
Intravitreal injection technique. Semin Ophthalmol (2011) 0.96
Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina (2007) 0.95
Genetic analysis of complement factor H related 5, CFHR5, in patients with age-related macular degeneration. Mol Vis (2009) 0.94
Anti-cyclic citrullinated peptide, rheumatoid factor, and ocular symptoms typical of rheumatoid arthritis. Trans Am Ophthalmol Soc (2008) 0.94
What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol (2013) 0.93
Associations of anisometropia with unilateral amblyopia, interocular acuity difference, and stereoacuity in preschoolers. Ophthalmology (2012) 0.93